Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Limitations of effective CD19-targeted chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory (R/R) B-cell lymphoma (BCL) include lack of sustained remissions and the potential for adverse effects such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). BTK inhibitors are immunomodulatory and may enhance CAR T-cell expansion, engraftment and tumor clearance while decreasing the frequency and severity of CRS (Gauthier, et al. Blood 2020).

Source: Biology of Blood and Marrow Transplantation - February 1, 2024 Category: Hematology Authors: Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Edus H Warren, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Jordan Gauthier, Alexandre V Hirayama, Stephen D Smith, Taran Gujral, Chihiro Morishima, Vicky Wu, Jenna M Voutsinas, Joshua Diz Tags: 37 Source Type: research